<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01541800</url>
  </required_header>
  <id_info>
    <org_study_id>2010-14205</org_study_id>
    <nct_id>NCT01541800</nct_id>
  </id_info>
  <brief_title>Circulating microRNAs as Disease Markers in Pediatric Cancers</brief_title>
  <official_title>A Feasibility Study of Circulating microRNAs as Disease Markers in Pediatric Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ann &amp; Robert H Lurie Children's Hospital of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      MicroRNAs are small molecules which have recently been discovered in cells. They are known to
      be responsible for the normal development of cells and when they are disrupted can contribute
      to the development of cancer. Many previous studies have been done evaluating the expression
      of microRNAs in normal tissues as well as a wide variety of cancers.

      Recently, microRNAs from tumor cells have been detected circulating in the blood of patients
      with cancer. This presents a novel opportunity to use microRNAs in the blood as an early
      predictor of cancer as well as a marker of response to therapy. No previous studies have been
      performed evaluating microRNAs in the blood or cerebrospinal fluid of patients with childhood
      cancers. We propose a feasibility study to evaluate the presence of microRNAs in the blood
      and cerebrospinal fluid of patients with central nervous system tumors, leukemia and lymphoma
      who are currently on chemotherapy and undergoing blood draws, lumbar punctures and/or
      reservoir taps for routine clinical care. If we're able to identify circulating microRNAs in
      this population of pediatric patients, we will build upon this data in proposing a future
      study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine if miRNAs are present in the blood of patients with pediatric cancers</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine if miRNAs are detectable in the CSF of patients with pediatric cancers.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Central Nervous System</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>All children who are in treatment for leukemia, lymphoblastic lymphoma and central nervous system tumors between 3 years and 21 years of age</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood and cerebral spinal fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All children who are in treatment for leukemia, lymphoblastic lymphoma and central nervous
        system tumors
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All children who are in treatment for leukemia, lymphoblastic lymphoma and central
             nervous system tumors

          -  age: greater than 3 years and less than or equal to 21 years of age

          -  Patients must be in a phase of their treatment during which routine blood draws,
             lumbar punctures or CSF sampling from Ommaya reservoirs are required for treatment of
             their cancers.

        Exclusion Criteria:

          -  Patients who have completed treatment and do not require routine blood draws and/or
             lumbar punctures

          -  Patients who are considered too ill to participate as determined by their treating
             physician

          -  Patients with a known genetic condition that predisposed them to the development of
             cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rishi Lulla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rishi Lulla, MD</last_name>
    <phone>312.227.4855</phone>
    <email>rlulla@luriechildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margaret Nevins</last_name>
    <phone>312.227.4861</phone>
    <email>mnevins@luriechildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Nevins</last_name>
      <phone>312-227-4861</phone>
      <email>mnevins@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Rishi Lulla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fernandez-L A, Northcott PA, Taylor MD, Kenney AM. Normal and oncogenic roles for microRNAs in the developing brain. Cell Cycle. 2009 Dec 15;8(24):4049-54. Epub 2009 Dec 5.</citation>
    <PMID>19901543</PMID>
  </reference>
  <reference>
    <citation>Roth C, Rack B, MÃ¼ller V, Janni W, Pantel K, Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 2010;12(6):R90. doi: 10.1186/bcr2766. Epub 2010 Nov 3.</citation>
    <PMID>21047409</PMID>
  </reference>
  <reference>
    <citation>Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008 Jul;110(1):13-21. doi: 10.1016/j.ygyno.2008.04.033. Erratum in: Gynecol Oncol. 2010 Jan;116(1):153.</citation>
    <PMID>18589210</PMID>
  </reference>
  <reference>
    <citation>Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008 May;141(5):672-5. doi: 10.1111/j.1365-2141.2008.07077.x. Epub 2008 Mar 3.</citation>
    <PMID>18318758</PMID>
  </reference>
  <reference>
    <citation>Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010 Jul 1;127(1):118-26. doi: 10.1002/ijc.25007.</citation>
    <PMID>19876917</PMID>
  </reference>
  <reference>
    <citation>Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009 Oct;58(10):1375-81. doi: 10.1136/gut.2008.167817. Epub 2009 Feb 6.</citation>
    <PMID>19201770</PMID>
  </reference>
  <reference>
    <citation>Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ. MicroRNAs as Novel Biomarkers for Breast Cancer. J Oncol. 2009;2009:950201. doi: 10.1155/2010/950201. Epub 2009 Jul 20.</citation>
    <PMID>19639033</PMID>
  </reference>
  <reference>
    <citation>Zhu W, Qin W, Atasoy U, Sauter ER. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes. 2009 May 19;2:89. doi: 10.1186/1756-0500-2-89.</citation>
    <PMID>19454029</PMID>
  </reference>
  <reference>
    <citation>Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE, Galas DJ. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4402-7. doi: 10.1073/pnas.0813371106. Epub 2009 Feb 25.</citation>
    <PMID>19246379</PMID>
  </reference>
  <reference>
    <citation>Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N. Plasma miR-208 as a biomarker of myocardial injury. Clin Chem. 2009 Nov;55(11):1944-9. doi: 10.1373/clinchem.2009.125310. Epub 2009 Aug 20.</citation>
    <PMID>19696117</PMID>
  </reference>
  <reference>
    <citation>Ai J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, Li K, Yu B, Li Z, Wang R, Wang L, Li Q, Wang N, Shan H, Li Z, Yang B. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun. 2010 Jan 1;391(1):73-7. doi: 10.1016/j.bbrc.2009.11.005. Epub 2009 Nov 5.</citation>
    <PMID>19896465</PMID>
  </reference>
  <reference>
    <citation>Zhang H, Luo XQ, Zhang P, Huang LB, Zheng YS, Wu J, Zhou H, Qu LH, Xu L, Chen YQ. MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia. PLoS One. 2009 Nov 13;4(11):e7826. doi: 10.1371/journal.pone.0007826.</citation>
    <PMID>19915715</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2012</study_first_submitted>
  <study_first_submitted_qc>February 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2012</study_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</investigator_affiliation>
    <investigator_full_name>Rishi Lulla</investigator_full_name>
    <investigator_title>Attending</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

